RME Course Instructors
Director, Wake Forest Institute for Regenerative Medicine
Anthony Atala, MD is a practicing surgeon and a researcher in the area of regenerative medicine. His work focuses on growing human cells, tissues and organs.
Dr. Atala works with several journals and serves in various roles, including Editor-in-Chief of: Stem Cells- Translational Medicine; Current Stem Cell Research and Therapy; Therapeutic Advances in Urology; and BioPrinting.
Dr. Atala is a recipient of awards, including the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, the Samuel D. Gross Prize in Surgical Research, the Innovation Award from the Society of Manufacturing Engineers, the Rocovich Gold Medal, and the Edison Science/Medical Award for work in 3D Bioprinting. In 2011 he was elected to the Institute of Medicine of the National Academy of Sciences, and in 2014 was inducted to the National Academy of Inventors as a Charter Fellow. Dr. Atala’s ongoing work has been described in the lay press. Dr. Atala’s work was listed in 2007 as Time Magazine’s top 10 medical breakthroughs of the year, by Discover Magazine in 2007 as the Number 1 Top Science Story of the Year in the field of medicine, by Smithsonian Magazine in 2010 as one of 40 things to know about the next 40 years, by Time Magazine in 2011 as one of the top 5 medical breakthroughs of the year, by the Huffington post in 2011 as one of 18 great ideas for the future, and by Time Magazine in 2013 as one of 5 discoveries that will change the future of organ transplants. Dr. Atala was named by Scientific American in 2010 as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration, by U.S. News & World Report in 2009 in as one of 14 Pioneers of Medical Progress in the 21st Century, by the American Association of Retired Persons in 2012 as one of the 50 influential people who will make life better, and by Scientific American in 2015 as one of the world’s most influential people in biotechnology.
Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the Bioengineering Consortium, the National Cancer Institute’s National Cancer Advisory Board, and was the Founder of the Regenerative Medicine Foundation. Dr. Atala heads a team of over 450 physicians and researchers. Over twelve applications of technologies developed in Dr. Atala’s laboratory have been used clinically.
He is the editor of fourteen books, including Principles of Regenerative Medicine, 3D Biofabrication, Essentials of Stem Cell Biology, and Methods of Tissue Engineering. He has published more than 500 journal articles and has applied for or received over 250 national and international patents.
Dr. Allickson has a doctorate in health sciences along with a master’s in medical laboratory sciences. An experienced scientist with regulatory expertise, she has more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products including business management and board directorship experience.
At the Institute, Dr. Allickson heads the clinical translation team streamlining development to create a robust pipeline of products in early phase clinical trials and FDA registered products including cell therapy, tissue engineered organs and tissues, biomaterials and devices. She is one of the founding members of the International Society of Cellular Therapy and has been a member of the American Association of Blood Banks (AABB) for 29 years. Dr. Allickson is on the Board of Directors for AABB and IWEUS Capital along with Regenerative Medicine Outcomes Foundation as a scientific advisor, editorial board of CELLR4, vice chair for Cord Blood Association Quality Committee, Technical Advisory Board for Tissue Engineered Products under ICCBBA, grant reviewer for state funded initiatives such as CIRM and serves on the ISCT Commercialization Committee.
Professor, Wake Forest Institute for Regenerative Medicine
Graça Almeida-Porada, M.D., Ph.D. is a Professor of Regenerative Medicine and the Director of the Fetal Research and Therapy Program at Wake Forest Institute for Regenerative Medicine. Dr. Almeida-Porada’s research focuses on the development of cellular and gene delivery platforms to treat genetic and immune-mediated diseases. She is particularly interested in improving the outcome of stem cell transplantation and gene therapy in fetal and neonatal patients with genetic disorders, and in developing therapies for children with immune-mediated diseases.
She has been a member of several NIH study sections, she serves as an Editor, or on the Editorial Boards, of several scientific journals, she is the co-editor-in-chief of Current Stem Cell Reports. She was inducted into Phi Beta Delta in 2006. She is the co-founder of the International Fetal Transplantation and Immunology Society. Dr. Almeida-Porada holds several patents and has authored more than 200 scientific works including papers, abstracts, and book chapters.
Professor, Wake Forest Institute for Regenerative MedicineDepartment of Chemical Engineering, Institute for Medical Engineering and Science, Harvard-MIT Division of Health Sciences & Technology; David H. Koch Institute for Integrative Cancer Research
Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science.
Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer products space including CRISPR Tx (Nasdaq:CRSP), Living Proof, Sigilon, Verseau Tx, and Olivo Labs.
Cellular and Tissue Therapy Branch, Center for Biologics Evaluation and Research, US FDA
Steven R. Bauer, Ph.D., is the Chief of the Cellular and Tissue Therapy Branch (CTTB), Division of Cellular and Gene Therapies (DCGT) in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). As the Chief of CTTB, Dr. Bauer supervises CBER scientific staff engaged in review of cell-based biological therapies, policy development in emerging areas of cellular therapies and regenerative medicine, and research relevant to their use in clinical trials. His current research focuses on multipotent stromal cell biology and stromal cell-hematopoietic cell interactions that influence development of lymphocytes.
Dr. Bauer received his Ph.D. in Biochemistry from the University of Maryland in 1986. From 1986 though 1991, Dr. Bauer was a scientific member of the Basel Institute for Immunology in Basel, Switzerland. In 1991, Dr. Bauer joined CBER’s Division of Cellular and Gene Therapies.
Professor, Biology; Director of the Skeletal Research Center at Case Western Reserve University
Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. He received his Ph.D. from The Johns Hopkins University School of Medicine.
Dr. Caplan is a national and international scholar focusing on experimentation in the area of musculoskeletal and skin development. He has published over 465 papers and manuscripts and has long been supported by the NIH and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal
tissues and for his pioneering research on Mesenchymal Stem Cells.
Dr. Jennifer Elisseeff is the Morton F. Goldberg Endowed Professor of ophthalmology and a professor orthopaedic surgery at the Johns Hopkins School of Medicine. She also holds appointments in the Johns Hopkins Department of Chemical and Biological Engineering and Department of Materials Science and Engineering. Her research focuses on tissue regeneration. Dr. Elisseeff is the Jules Stein Professor of Ophthalmology and director of the Translational Tissue Engineering Center.
Her team is engaged in engineering technologies to repair lost tissues. Specifically, she is examining hydrogels as a scaffold for tissue engineering and is working to develop an artificial cornea.
Dr. Elisseeff received a bachelor's degree in chemistry from Carnegie Mellon University and a Ph.D. in medical engineering from the Harvard-MIT Division of Health Sciences and Technology. After doctoral studies, Dr. Elisseeff was a fellow at the National Institute of General Medical Sciences Pharmacology Research Associate Program. She joined the Johns Hopkins faculty in 2001.
Medical Officer, Emmes
Dr. El Fiky is a Harvard-trained and educated clinical research expert and is currently is a full-time Medical Officer at a global regulatory and clinical research consulting firm, EMMES, headquartered in the Washington DC metropolitan region. His duties include medical monitoring, phramacovigilance, drug risk assessment/mitigation and regulatory oversight of clinical trials assessing safety and efficacy of novel drugs, vaccines and stem cell therapies.
Dr. El Fiky received his medical degree from Egypt's University of Alexandria and Ph.D. in Experimental Pathology/Immunology from the University of California-Irvine. His clinical training specialized in infection control and laboratory medicine particularly molecular identification of virulence factors of endemic vector- and blood-borne pathogens. Dr. El Fiky’s PhD thesis and postdoctoral research revealed a novel signaling mechanism for type I interferon and investigated molecular signaling mechanism of cytokines in cancer, inflammation, and allergic pathogenesis. After completing his medical training and ABMM- approved fellowship, he continued postdoctoral training at the NIH’s National Cancer Institute, National Institute of Allergy and Infectious Diseases, and the FDA’s Office of Vaccine Research and Review. He completed his clinical trial training at Harvard Medical School.
Dr. El Fiky co-authored peer-reviewed novel research publications in addition to a book chapter on clinical and regulatory pathway of stem cell-based therapy in the United States.
Dr. El Fiky was awarded Harvard University’s clinical research scholarship, the FDA’s Commissioner Citation Award and the University of California’s William Holcomb Award for Excellence in Biomedical Research.
Dr. El Fiky gave a lecture at the 2017 and the 2019 TERMIS meetings in Charlotte, NC and Orlando, FL, respectively, on the regulatory pathway for mesenchymal stromal cell-based therapy in the United States focusing on the NIH’s Production Assistance for Cell Therapy (PACT) program.
AO Research Institute Davos, Switzerland
Sibylle Grad is a Principal Scientist at the AO Research Institute Davos (ARI), Switzerland. She is the deputy Program Leader of the Regenerative Orthopaedics Program and the focus area leader for intervertebral disc and cartilage research. Sibylle Grad obtained her PhD in Natural Sciences from the Department of Cell Biology of the Federal Institute of Technology in Zürich (ETHZ), Switzerland. After completing her first post-doctoral training, she joined the AO Research Institute Davos to set up a cartilage bioreactor system. She has since then acquired extensive research expertise in tissue engineering and regenerative medicine with focus on cartilage and intervertebral disc repair and regeneration. Her projects include whole organ culture models and bioreactors for intervertebral disc disorders, cell therapy, molecular therapy, annulus fibrosus repair, circulating and tissue biomarkers; bioreactor loaded explant models for cartilage and osteochondral defects. Her expertise in advanced ex-vivo organ culture systems for studying both disease/ degeneration and repair/ regeneration in orthopedic research is widely acknowledged. Sibylle Grad is also a private docent with habilitation at the ETHZ and course leader in the graduate program of the ETH Department of Health Science and Technology. She has obtained funding from many national, European and international agencies, and has been section leader and partner of several collaborative projects. She is a co-organiser of the eCM Annual Conference and has served as Topic Chair, Spine section research chair, and program committee member of the Orthopaedic Research Society. Her publication list includes more than 115 peer-reviewed articles and 10 book chapters.
Chief Technology Officer, RegenMed Development Organization (ReMDO); Executive Director, Regenerative Medicine Manufacturing Society (RMMS)
Dr. Hunsberger obtained his B.A. in neuroscience from Wesleyan University and his Ph.D. in neuroscience from Yale University where his work focused on the beneficial effects of exercise in treating depression. He then did his postdoctoral work at the National Institutes of Health where he was the Julius Axelrod Post Doctoral Fellow and worked in areas of mood disorders and stroke. He then was a research fellow at the National Institutes of Health Center for Regenerative Medicine where he coordinated efforts for advancing clinical translation of stem-cell technologies. He then came to Wake Forest Institute for Regenerative Medicine where he worked on various director initiatives seeking to translate regenerative medicine technologies into the clinic to treat patients.
Dr. Hunsberger is currently chief technology officer of a non-profit organization, RegenMed Development Organization (ReMDO) that is advancing regenerative medicine manufacturing platform technologies in pre-competitive space. One of the programs focuses on development of a universal media to support clinical cell manufacturing. The other program focuses on development of a tunable bioink system for 3D bioprinting. He is also executive director of the Regenerative Medicine Manufacturing Society (RMMS) which is a professional society that has a vision of enabling the adoption of manufacturing platform technologies into standards, regulatory pathways, and commercial products by assembling a diverse network of stakeholders.
Associate Professor, Wake Forest Institute for Regenerative Medicine
Dr. John D. Jackson is an Associate Professor in the Institute for Regenerative Medicine at Wake Forest School of Medicine, Winston Salem, NC. He received his Ph.D. degree in Medical Sciences (Experimental Hematology) from the University of Nebraska Medical Center, Omaha, NE. He received post-doctoral training at DNAX Research Institute, Palo Alto, CA. At DNAX Research Institute, Dr. Jackson was involved in research directed to the study of the role of cytokines in the regulation of hematopoietic and immune systems.
In 1990, Dr. Jackson joined the Department of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, NE as an Assistant Professor. He was also appointed Technical Director of the Cell Processing Laboratory at the University of Nebraska Medical Center which provided support for the bone marrow transplantation program. His research focus during this time was directed toward the effects of cytokines and other agents on hematopoietic mobilization for transplantation as well as hematopoietic and immunological recovery following transplantation. In 2010, Dr. Jackson moved to Wake Forest School of Medicine and serves as an Associate Professor in the Institute for Regenerative Medicine. His research interests have broadened to include engineering of tissues and organs including skin, inner ear, muscle, bone, cartilage, kidney, ovary and corporal tissue.
Professor, Department of Social Sciences and Health Policy, Wake Forest School of Medicine; Professor, Wake Forest Institute for Regenerative Medicine; Co-Director, Center for Bioethics, Health and Society and Graduate Program in Bioethics, Wake Forest University
Nancy M. P. King, JD, is Professor in the Department of Social Sciences and Health Policy and Wake Forest Institute for Regenerative Medicine at Wake Forest School of Medicine, and Co-Director of the Center for Bioethics, Health, and Society and the Graduate Program in Bioethics at Wake Forest University. Her scholarship addresses a range of bioethics issues, including: informed consent, benefit, and uncertainty in health care and research; the development and use of experimental technologies; international and cross-cultural questions in human subjects research; and ethical issues in “big data” research and biobanking, gene transfer research, regenerative medicine, and other novel biotechnologies.
Professor King has published over 100 scholarly articles and book chapters, and is co-editor of The Social Medicine Reader (2nd ed., Duke University Press, 2005; 3rd ed. forthcoming), Beyond Regulations: Ethics in Human Subjects Research (UNC Press 1999), and Bioethics, Public Moral Argument, and Social Responsibility (Routledge 2012). She teaches a variety of courses in bioethics, medical humanities, and research ethics to medical students and faculty and to graduate students in bioethics and the health sciences.
Professor King has served on hospital ethics committees, IRBs, DSMBs and the NIH Recombinant DNA Advisory Committee, and has taught bioethics in national and international settings. She is a Fellow of the Hastings Center and a member of the DHHS Secretary’s Advisory Committee for Human Research Protections.
Associate Professor (Tenured), Wake Forest Institute for Regenerative Medicine
Deputy Director, Tissue Engineering Program; Director, Biofabrication Core
Wake Forest School of Medicine
Sang Jin Lee, Ph.D. is currently a tenured Associate Professor at Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest School of Medicine. Dr. Lee received his Ph.D. in Chemical Engineering at Hanyang University, Seoul, Korea in 2003 and took a postdoctoral fellowship in the Laboratories for Tissue Engineering and Cellular Therapeutics at Harvard Medical School and Children’s Hospital Boston and the WFIRM where he is currently a faculty member. He is also cross-appointed to the Virginia Tech-WFU Biomedical Engineering and Science. Dr. Lee has authored more than 140 scientific publications and reviews, has edited 2 textbooks, and has written 34 chapters in several books.
Dr. Lee has extensive knowledge and experience in biomaterials science, especially, biodegradable polymers and tunable hydrogels, with specific training and expertise in key research areas for tissue engineering and regenerative medicine. His research team has developed various biomaterial systems that improve cellular interactions by providing appropriate environmental cues. These biomaterial systems consist of drug/protein delivery systems, nano/micro-scaled topographical features, and hybrid materials that can actively participate in functional tissue regeneration. Recently, his team is utilizing automated 3D bioprinting technology to manufacture complex, multi-cellular living tissue constructs that mimic the structure of native tissues. This can be accomplished by optimizing the formulation of biomaterials to serve as bioinks for 3D bioprinting, and by providing the biological microenvironment needed for the successful delivery of cells and biomaterials to discrete locations within the 3D structure.
Scripps Research Institute
Jeanne F. Loring is Professor emeritus at the Scripps Research Institute where she was founding Director of the Center for Regenerative Medicine. Dr. Loring has diverse experience: 15 years in biotechnology and 15 years of academic research, combining stem cells, genomics, epigenetics, bioinformatics, embryology and neurobiology. She has founded two stem cell-based biotechnology companies, Arcos Bioscience (now part of Viacyte) and Aspen Neuroscience, a biotechnology company founded in 2018 to continue development of an autologous neuron replacement therapy for Parkinson disease. She holds five patents on stem cells and genomics, and has published three books and more than 120 research articles.
In addition to her work on Parkinson disease, Dr. Loring investigates stem cell-based therapies for multiple sclerosis, studies the cellular basis for autism, and works with the San Diego Zoo Institute for Conservation Research in an effort to rescue the Northern white rhinoceros from extinction using stem cell technology. She is also involved in a project on the International Space Station to study neurogenerative disease in microgravity.
Dr. Loring is recipient of many awards for her accomplishments both as a scientist and an advocate for evidence-based therapies for patients and education. Through her NIH- and CIRM-sponsored laboratory courses, she has trained more than 400 scientists in stem cell technology. She serves on bioethics and scientific advisory boards, is on the editorial boards of several scientific journals, and advises governmental and private granting agencies in several countries. She is frequently interviewed for news reports about topics including cell and gene therapies, patient rights, the ethics of stem cell tourism, experiments in space, rescue of endangered species, and challenges for women in science and as entrepreneurs in biotechnology. She gives talks about her work at international conferences, is the featured speaker on numerous podcasts and webinars, is interviewed often by television networks, and has appeared in several documentaries.
Professor, Wake Forest Institute for Regenerative Medicine
Frank Marini is a professor at the Wake Forest Institute for Regenerative Medicine, with affiliation in the Department of Cancer Biology and the Center on Diabetes, Obesity and Metabolism at the Wake Forest School of Medicine. Marini earned his PhD at the University of Texas MD Anderson Hospital in 1998. His expertise includes molecular biology and microscopic imaging.
Assistant Professor, Wake Forest Institute for Regenerative Medicine
Dr. Sean Murphy received his Bachelors degree in Molecular Biology (Honors) from the University of Western Australia in 2006 and his Ph.D. in Stem Cell Therapy in 2012. His thesis work focused on developing perinatal stem cells as a therapy for lung disease and contributed to an ongoing Phase I clinical trial for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants. Dr. Murphy joined Wake Forest Institute for Regenerative Medicine in 2012 as a Postdoctoral Fellow and became an Assistant Professor in 2015.
Chairman and CEO, Histogen, Inc.
Gail K. Naughton, Ph.D., founded Histogen, Inc., a regenerative medicine company, in 2007, and currently serves as CEO and Chairman of the Board. In addition, Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 through 2011. Prior to that, she spent more than 15 years at Advanced Tissue Sciences, where she was the company’s co-founder and co-inventor of its core technology. During her tenure there, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. Dr. Naughton holds over 100 U.S. and foreign patents and has been extensively published in the field of tissue engineering and regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering.
Dr. Naughton serves as a director for several not-for-profit foundations and also sits on the scientific and industry advisory boards of leading universities including the Georgia Institute of Technology, the SDSU College of Business Administration Board, the advisory board of the Lavin Entrepreneurial Management Center, and Perminova. She is also a member of the San Diego State University Corporate Governance Institute and sits on two public boards, C.R. Bard, Inc. and Cytori Therapeutics Inc.
She has received numerous awards for her leadership in both science and business including the 1998 ARCS Association, National Scientist of the Year, 2001 Women of the New Millenium Award, presented by Feminine Fortunes Magazine, Volume 2, 2001, Lindbergh-Carrel Prize for outstanding contributions to the development of perfusion and bioreactor technologies for organ preservation and growth presented by Charles and Anne Lindbergh Foundation and Alexis Carrel Foundation and the 2006 “Woman of the Year” award by San Diego Magazine.
Dr. Naughton earned her Ph.D. in Basic Medical Sciences and her M.S. in histology from the New York University Medical Center. She earned an executive MBA in 2001 from the Anderson School at the University of California, Los Angeles.
The Nakayama Laboratory works on developing engineered and regenerative therapies to treat cardiovascular and musculoskeletal injuries and disease. Dr. Nakayama received her Ph.D. from the Department of Biomedical Engineering at the University of California, Davis. During her doctoral training, she worked towards developing regenerative therapies for congenital kidney diseases using decellularized extracellular matrices and stem cell-derived renal precursors.
Dr. Nakayama completed her postdoctoral training at the Stanford University School of Medicine in the Department of Cardiothoracic Surgery. During her time at Stanford, her research focused on building iPSC-derived small diameter vascular grafts and myocardial tissues and enhancing angiogenesis in ischemic and severely damaged limbs through the manipulation of the spatial and mechanical properties of biomaterials.
Dr. Nakayama joined the faculty at Oregon Health & Science University (OHSU) in the Department of Biomedical Engineering in January of 2020. The current research focus of the Nakayama Lab is the development of regenerative therapies for cardiovascular and musculoskeletal disease and injury using spatially patterned biomaterials and rehabilitation exercise.
Professor, Wake Forest Institute for Regenerative Medicine
Dr. Christopher Porada received his Bachelor’s degree in Molecular Biology from Colgate University in 1991 (magna cum laude, Phi Beta Kappa) and his PhD in Cellular and Molecular Pharmacology and Physiology from the University of Nevada in 1998 (summa cum laude), focusing on fetal gene therapy for the treatment of hematologic diseases. After completing his PhD, he conducted a post-doctoral fellowship in the Department of Medicine at the VA Medical Center in Reno, focusing on stem cell biology and the immune aspects of gene delivery. In 2001, he joined the Department of Animal Biotechnology at the University of Nevada, Reno as an Assistant Professor, and was subsequently promoted to an Associate Professor at the same Institution. He has authored over 125 scientific abstracts, over 60 full-length manuscripts, and has written chapters in nearly a dozen books. He serves on the Editorial Board for several international journals, and is a member of several international societies. Dr. Porada regularly serves as a reviewer for NIH, NYSTEM, several other international grant agencies, and over 40 international journals focused on gene therapy, gene and drug delivery, stem cell biology, cancer, and stem cell transplantation. Dr. Porada joined the faculty at WFIRM in 2011.
Joan’s work is focused on providing high quality educational programming within the field of tissue engineering and regenerative medicine. In her role, she also works to increase awareness of the Institute’s leadership role within the field of biomedicine. Joan's professional background includes more than 20 years of specialized experience in administration, education, research, fund raising, collaborative team building, program development and direct care/services delivery within the university, community and non-profit, public health, and education setting. Throughout her career, she has recognized the importance of education and the need to develop collaborative, multidisciplinary education and research training across formal and informal educational environments.
Executive Director, Regenerative Medicine Foundation
Bernard Siegel is the executive director of the nonprofit Regenerative Medicine Foundation (RMF), with a mission of accelerating regenerative medicine to improve health and deliver cures.
Bernie founded and co-chairs the annual World Stem Cell Summit and RegMed Capital Conference, founded and serves editor–in–chief of the peer-reviewed “World Stem Cell Report” (AlphaMed Press).
In 2002, he filed the first court case relating to reproductive cloning and is widely credited for debunking the claim of the group claiming that they cloned the first baby. As a recognized advocacy and policy expert in the fields of stem cell research, regenerative medicine and related subjects, Bernie works with the leading scientists and patient advocates, raising public awareness and educating lawmakers, the media and public. He is a frequent conference panelist and keynote speaker.
Professor, Sanford Burnham Prebys Institute & Department of Pediatrics, University of California-San Diego
Dr. Snyder earned his M.D. and his Ph.D. in neuroscience from the University of Pennsylvania in 1980. He completed residencies in pediatrics and neurology at Children's Hospital-Boston, Harvard Medical School and postdoctoral research at Harvard Medical School. In 1992, Dr. Snyder was appointed an instructor in neurology at Harvard Medical School and was promoted to assistant professor in 1996.
Dr. Snyder is regarded as one of the fathers of the stem cell field, having identified over 2 decades ago that cells that came to be called stem cells were a source of neural plasticity. He was the first to demonstrate that non-hematopoietic stem cells could mediate cell and gene replacement, home to injury, and perform protective, trophic, pro-regenerative, and anti-inflammatory actions. He was the first to isolate human neural stem cells. In 2003, after 23 years at Harvard, Dr. Snyder was recruited to Sanford Burnham Prebys Medical Discovery Institute as professor and director of the Stem Cells and Regeneration program.
Director, McGowan Institute for Regenerative Medicines
Dr. Wagner is Director of the McGowan Institute for Regenerative Medicine as well as Distinguished Professor of Surgery, Chemical Engineering, and Bioengineering at the University of Pittsburgh. He serves as Scientific Director of the NSF Engineering Research Center on “Revolutionizing Metallic Biomaterials” and Chief Science Officer for the Armed Forces Institute of Regenerative Medicine. He holds a B.S. (Johns Hopkins Univ.) and Ph.D. (Univ. of Texas) in Chemical Engineering.
Professor Wagner is the Founding Editor and Editor-in-Chief of one of the leading biomaterials journals, Acta Biomaterialia. He is past-president of the American Society for Artificial Internal Organs (ASAIO) and past chairman of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Americas region. He is a fellow and former vice president of the American Institute for Medical and Biological Engineering (AIMBE) and has also been elected a fellow of the Biomedical Engineering Society, the International Union of Societies for Biomaterials Science and Engineering, TERMIS, and the American Heart Association. In 2006, he was selected to the “Scientific American 50”, the magazine’s annual list recognizing leaders in science and technology from the research, business and policy fields. His research has generated numerous patents (35 issued to date) and patent filings that have resulted in licensing activity, the formation of two companies, one of which initiated two clinical trials. Transfer of his group’s intellectual property has been recognized with University of Pittsburgh Innovator Awards in 2007, 2008, 2009, 2010, 2014, 2017 and 2018. Some of his awards include the Society for Biomaterials Clemson Award for Applied Research, the Chancellor’s Distinguished Research Award from the University of Pittsburgh, and the Senior Investigator Award from TERMIS-Americas. In 2017, he was inducted as a fellow of the National Academy of Inventors and in 2018 he was named Inventor of the Year by the Pittsburgh Intellectual Property Law Association.
In 2019, Dr. Wagner was promoted to the rank of Distinguished Professor, the highest recognition available to University of Pittsburgh faculty. In 2020, the 4th edition of the best-selling biomaterials textbook, “Biomaterials Science” was published with Dr. Wagner taking over the lead editor role and in partnership with a new generation editorial team. Dr. Wagner's research interests are in cardiovascular engineering with projects that address medical device biocompatibility and design, biomaterial development, and tissue engineering.
Professor and Director of International Affairs, Wake Forest Institute for Regenerative Medicine
Professor Williams has had 50 years experience in biomaterials, medical device and tissue engineering. During his career he has published over 35 books and 430 papers: his latest book, Essential Biomaterials Science was published by Cambridge University Press in 2014. He was Editor-in-Chief of Biomaterials, the world’s leading journal in this field for 15 years. He has received the major awards from the US, European and Indian societies of biomaterials including the Founders Award of the US Society for Biomaterials in 2007, and received the prestigious Acta Biomaterialia Gold Medal in 2012. In 1999 he was elected as a Fellow of the Royal Academy of Engineering, UK, and is a Foreign Fellow of the Indian National Academy of Engineering and a Fellow of the American Institute of Medical and Biological Engineering, all in recognition of his contributions to engineering in medicine. He was global President of the Tissue Engineering & Regenerative Medicine International Society between 2012 and 2015.
Professor Williams left the University of Liverpool, UK, in 2007, where he had been Head of Clinical Engineering, Director of the UK Centre for Tissue Engineering and Pro Vice Chancellor of the University. While retaining the title of Emeritus Professor at Liverpool, he is currently Professor and Director of International Affairs, Wake Forest Institute of Regenerative Medicine, North Carolina, USA. In addition, he is a Visiting Professor in the Christiaan Barnard Department of Cardiothoracic Surgery, Cape Town, South Africa, a Visiting Professorial Fellow at the Graduate School of Biomedical Engineering, University of New South Wales, Australia, and a Guest Professor, at Tsinghua Universities, Beijing, and Advisory Professor at Shanghai Jiao Tong University, China. . In Cape Town, along with Professor Peter Zilla, the current Chris Barnard Professor of Surgery, he formed a company that will produce low cost but high technology medical devices that can be used with minimally invasive procedures to treat young adults in sub-Sarah Africa, who currently have no therapies available to them. After 8 years work, and raising the equivalent of $30 million within Africa, his team successfully used their non-occlusive delivery system in a First-in-Man experience in January 2019, the first in the world.
Dr. Yoo is a surgeon and researcher. He is currently a faculty member at the Wake Forest Institute for Regenerative Medicine and is cross-appointed to the Department of Urology, Physiology and Pharmacology, and Biomedical Engineering. Dr. Yoo received his Bachelor’s Degree in biology from the University of Illinois in 1984.